Zalifrelimab

Phase 2Monoclonal antibody

AAgenus Inc.

Zalifrelimab is one of 150 small molecule programs targeting Pancreatic Cancer. It is currently in Phase 2.

Indications

Total Trials

Active Trials

149

Competitors

Pipeline

Status by Indication[3][1]

Indication

Pancreatic CancerActive, not recruiting

ALSRecruiting

Newly DiagnosedRecruiting

Soft Tissue SarcomaRecruiting

Pancreatic CancerPhase 2

Active, not recruiting

ALSPhase 2

Recruiting

Newly DiagnosedPhase 1

Recruiting

Soft Tissue SarcomaPhase 2

Recruiting

Competition

Competitive Landscape

307 competitors in Pancreatic Cancer

#DrugCompanyPhaseTrials

Zalifrelimab

AAgenus Inc.

Phase 2

1 2

Byetta

AstraZeneca

Preclinical

1 3

Medrol

Pfizer

Preclinical

1 4

MS Contin

HHikma Pharmaceuticals LLC

Preclinical

1 5

Xylocaine

MMEDRx USA, Inc.

Preclinical

1 6

Feraheme

AAzurity Pharmaceuticals

Preclinical

1 7

Active Comparator

Moderna

Preclinical

1 8

Secretin-Ferring

Ferring

Preclinical

1 9

Sulfonylureas

Eli Lilly

Preclinical

1 10

Concurrent Lenvatinib

TTrans Tasman Radiation Oncology Group

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

Phase 1Recruiting

Newly Diagnosed

NCT04943848

Q4 2027

Phase 2Recruiting

Soft Tissue Sarcoma

NCT04028063

Q1 2028

PreclinicalActive, not recruiting

Metastatic Prostate Cancer

NCT06782555

Clinical

Trials by Indication[1]

Soft Tissue Sarcoma1 trial

Doxorubicin Plus Dual Checkpoint Blockade for Soft Tissue Sarcomas

Recruiting·UUniversity of Colorado, Denver·Phase 2·NCT04028063·65 enrolled

Pancreatic Cancer1 trial

Study to Evaluate the Safety and Efficacy of Treatment With NLM-001 and Standard Chemotherapy Plus Zalifrelimab in Patients With Advanced Pancreatic Cancer

Active, not recruiting·NNelum Corp·Phase 1/2·NCT04827953·28 enrolled

Refractory Cancer1 trial

AGEN1884, an Anti-CTLA-4 Human Monoclonal Antibody in Participants With Advanced or Refractory Cancer and Who Have Progressed With PD-1/PD-L1 Inhibitor as Their Most Recent Therapy

Completed·AAgenus Inc.·Phase 1/2·NCT02694822·89 enrolled

Newly Diagnosed1 trial

rHSC-DIPGVax Plus Checkpoint Blockade for the Treatment of Newly Diagnosed DIPG and DMG

Recruiting·—·Phase 1·NCT04943848·36 enrolled

Metastatic Prostate Cancer1 trial

A Phase 1/2 Immunotherapy Study of Evofosfamide in Combination With Zalifrelimab and Balstilimab in Patients With Advanced Solid Malignancies

Active, not recruiting·IImmunoGenesis·Preclinical·NCT06782555·71 enrolled

2 more indications

Cervical Cancer1 trial

A Phase 1/2, Open-Label, Multi-Arm Trial to Investigate the Safety, Tolerability, Pharmacokinetics, Biological, and Clinical Activity of AGEN1884 in Combination With AGEN2034 in Subjects With Metastatic or Locally Advanced Solid Tumors, and Expansion Into Select Solid Tumors

Completed·AAgenus Inc.·Preclinical·NCT03495882·175 enrolled

Unspecified1 trial

Expanded Access for Cancer Treatment With Balstilimab (AGEN2034), Either as Monotherapy, or as Used in Combination With Zalifrelimab (AGEN1884)

Available·AAgenus Inc.··NCT05572970

Sources

References

[1]
ClinicalTrials.gov — 7 trial records for Zalifrelimab. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Zalifrelimab compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Zalifrelimab. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Agenus Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Monoclonal antibody[2]
Highest Phase: Phase 2[1]
Company: AAgenus Inc.

Zalifrelimab

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2027

Q4 2027

Q1 2028

Trials by Indication[1]

Soft Tissue Sarcoma1 trial

Pancreatic Cancer1 trial

Refractory Cancer1 trial

Newly Diagnosed1 trial

Metastatic Prostate Cancer1 trial

Cervical Cancer1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News